Table 1.
Correlation of GNL3L expression with clinical and laboratorial parameters in patients from AML-HNCH cohort.
| Parameters | Total (n = 78) | GNNL3L Expression | p Value | |
|---|---|---|---|---|
| High (n = 39) | Low (n = 39) | |||
| Gender: male/female | 42/36 | 22/17 | 20/19 | 0.65 |
| Age, median (range) | 57 (14-86) | 60 (18-86) | 62 (14-84) | 0.77 |
| WBC 109/L, median (range) | 24 (15.2-233.5) | 32 (15.2-233.5) | 20.4 (18-217) | 0.05 |
| Hemoglobin g/L, median (range) | 71 (22-155) | 65 (22-145) | 76 (25-155) | 0.13 |
| Platelets × 109/L, median (range) | 50 (12-450) | 42 (12-417) | 55 (19-450) | 0.46 |
| Median BM blasts %, (range) | 62.0 (23.0-95.0) | 75.0 (34.0-95.0) | 52.3 (23.0-89.5) | 0.06 |
| Cytogenetic risk (%) | 0.12 | |||
| Favorable | 20 (25.6) | 6 (15.4) | 14 (35.9) | |
| Intermediate/normal | 32 (41.0) | 18 (46.1) | 14 (35.9) | |
| Poor | 26 (33.4) | 15 (38.5) | 11 (28.2) | |
| FAB classifications, n (%) | 0.57 | |||
| M0 | 5 (6.4) | 3 (7.7) | 2 (5.1) | |
| M1 | 8 (10.3) | 5 (12.8) | 3 (7.7) | |
| M2 | 11 (14.1) | 7 (18.0) | 4 (10.3) | |
| M3 | 18 (23.1) | 5 (12.8) | 13 (33.3) | |
| M4 | 16 (20.5) | 9 (23.0) | 7 (18.0) | |
| M5 | 15 (19.2) | 8 (20.5) | 7 (18.0) | |
| M6 | 3 (3.8) | 1 (2.6) | 2 (5.0) | |
| M7 | 2 (2.6) | 1 (2.6) | 1 (2.6) | |
WBC: blood cell; BM: bone marrow; FAB: French-American-British.